Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Nov 06, 2024 11:22am
47 Views
Post# 36298912

RE:RE:RE:RE:Jobs at LABS

RE:RE:RE:RE:Jobs at LABS
Lemoyne wrote: Ahah, I didn't intend this message to hit you so hard, honestly. I'm an analyst, so I do have trouble with everything misinformation/ lack of critical reflection, especially in this day and age. It's not personal, I would've commented the same for anyone posting this kind of information.

As for my love affair with Keith, I would answer this: Is your opinion of Keiths uselessness impacting the way you interpret information/ bias? For me, that's a reasonable explanation of the post you made this morning.



How you decide to hit or how hard it totally up to you and certainly it doesn't bother me one way or the other what you believe my competency level to be. 

One might assume that an aspect (perhaps large) of Strachan's role was local medical so it is not unreasonable that this new role is going to inherit a portion of his portfolio AND at a much lower salary than he was making, so while I wasn't as clear as I ought to have been, nothing in my post is 'misinformation' is simply a statement of opinion.  Posting for a sales role (local or otherwise) shortly after shuffling out the 'sales and marketing' President has some optics associated with it.

And make no mistake, I personally didn't/don't find Strachan 'useless' but as an investor, as the sales and marketing guy C-suite guy, he has a hand in the SP being at an all-time low level so I'm not willing to give him a pass on that until the international/national partners/channels etc do some meaningful business.  More than willing to claim mea culpa if Q3 hits big or we're taken out for north of a loonie however.  lol
<< Previous
Bullboard Posts
Next >>